All In Biotech

Drug Trial Radar · NCT07831902

Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer

Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) No Specific Molecular Profile (NSMP) - ORANGE Trial

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Jun 29, 2026

Primary completion

Dec 2030

Study completion Dec 2034

Sponsor

Lead sponsor
University College, LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RAINBO NSMP-ORANGE aims to investigate if adjuvant radiotherapy with oral progestin tablets is as effective as radiotherapy with chemotherapy, whilst reducing toxicity and thus improving quality of life, in patients with high-risk NSMP endometrial cancer. Patients will be randomised to radiotherapy with chemotherapy (standard of care), or radiotherapy followed by oral progestin tablets.

Conditions

  • Endometrial Cancer
  • Uterine Neoplasms

Interventions

  • medroxyprogesterone acetate tablets OR megestrol acetateDrug

    Medroxyprogesterone acetate 200mg once daily OR megestrol acetate 160mg once daily following completion of radiotherapy, for 24 months (2 years)

  • CisplatinDrug

    carboplatin and paclitaxel +/- cisplatin, as per standard of care/investigator decision, with radiotherapy

  • Carboplatin + PaclitaxelDrug

    carboplatin and paclitaxel +/- cisplatin, as per standard of care/investigator decision, with radiotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence free survival (RFS)Time frame: 3 years

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Royal United Hospitals Bath

    Bath, United Kingdom · Recruiting

  • Cheltenham General

    Cheltenham, United Kingdom · Recruiting

  • Leicester Royal Infirmary

    Leicester, United Kingdom · Recruiting

  • Bartholemew's Hospital

    London, United Kingdom · Recruiting

  • Royal Marsden (Chelsea)

    London, United Kingdom · Recruiting

  • University College London Hospital (UCLH)

    London, United Kingdom · Recruiting

  • The Christie

    Manchester, United Kingdom · Recruiting

  • James Cook University Hospital

    Middlesbrough, United Kingdom · Recruiting

  • Churchill

    Oxford, United Kingdom · Recruiting

  • Queen Alexandra Hospital

    Portsmouth, United Kingdom · Recruiting

  • University Hospital Southampton

    Southampton, United Kingdom · Recruiting

  • Royal Marsden (Sutton)

    Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.